



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



AZD 1656

Item No. 41839

CAS Registry No.: 919783-22-5

Formal Name: 3-[[5-(1-azetidinylcarbonyl)-2-pyrazinyl]oxy]-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methyl-2-pyrazinyl)-benzamide

MF: $C_{24}H_{26}N_6O_5$


FW: 478.5

Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZD 1656 is supplied as a solid. A stock solution may be made by dissolving the AZD 1656 in the solvent of choice, which should be purged with an inert gas. AZD 1656 is soluble (≥ 10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in ethanol.

Description

AZD 1656 is an activator of hexokinase-4 (HK4).¹ It activates HK4 and induces glucose phosphorylation in a cell-free assay ($EC_{50} = 61$ nM). AZD 1656 (0.3 mg/kg) decreases blood glucose levels in an oral glucose tolerance test (OGTT) in rats. It reduces blood glucose levels and increases plasma insulin levels in mice when administered at doses of 2, 4.5, or 9 mg/kg.²

References

1. Waring, M.J., Clarke, D.S., Fenwick, M.D., *et al.* Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656. *MedChemComm* **3**(9), 1077 (2012).
2. Ford, B.E., Chachra, S.S., Alshawi, A., *et al.* Chronic glucokinase activator treatment activates liver carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge. *Diabetes Obes. Metab.* **22**(11), 1985-1994 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/05/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM